20 completed, 19 unknown, 13 recruiting, 6 active not recruiting. 27 Phase 2, 13 Phase 1, 10 Phase 3, 9 Not applicable, 1 Early Phase 1.
Follow Nasopharyngeal Cancer: new trials by email Literature Review of Nasopharyngeal Cancer trials Research Report on Nasopharyngeal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-09-01 | 2026-08-11 |
| Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Gemcitabine + cisplatin (GP) - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 514 | 2026-04-01 | 2026-04-13 |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Gemcitabine (GEM), Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 412 | 2026-03-01 | 2026-02-03 |
| Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2) - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 418 | 2026-01-15 | 2026-01-28 |
| Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment Gelclair Oral Mouth Rinse - Squamous Cell Carcinoma, Oropharyngeal Cancers | Phase 4 | Active not recruiting | McMaster University | 29 | 2025-12-15 | 2026-07-13 |
| QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. QL1706, Gemcitabine, Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Recruiting | Sun Yat-Sen University Cancer Center | 580 | 2025-05-04 | 2025-05-22 |
| Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma Intensity-Modulated Radiation Therapy (IMRT), Radiographic Imaging, Biospecimen Collection - Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8 | Not applicable | Recruiting | University of California, San Francisco | 66 | 2025-03-18 | 2026-06-17 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy Nasopharyngeal Carcinoma, Head and Neck Cancer | Unknown | The Christie NHS Foundation Trust | 10 | 2024-08-30 | 2024-06-28 | |
| Adebrelimab and Chemoradiotherapy in High-risk LANPC Adebrelimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 50 | 2024-07-23 | 2025-01-15 |
| Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy Irinotecan Liposomal combined With Nituzumab - Nasopharyngeal Cancer | Phase 2 | Active not recruiting | XIANG YANQUN | 38 | 2024-05-22 | 2024-12-30 |
| 68Ga-FAPI-46 PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma Patients Nasopharyngeal Cancer | Completed | The First Affiliated Hospital of Xiamen University | 31 | 2024-01-31 | 2025-08-24 | |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors BL-B01D1 - Non Small Cell Lung Cancer, Esophageal Cancer | Phase 1 | Recruiting | SystImmune Inc. | 540 | 2023-08-08 | 2026-09-21 |
| Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) Cadonilimab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 3 | Active not recruiting | Sun Yat-sen University | 490 | 2023-08-01 | 2025-01-23 |
| Arabic PRO Measures for Head and Neck Cancer Radiotherapy. Radiation - Head and Neck Cancer, Head and Neck Neoplasms | Recruiting | King Saud University | 125 | 2023-05-01 | 2024-10-29 | |
| Nivolumab in Children and Adults With Nasopharyngeal Carcinoma Nivolumab, Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 2 | Recruiting | German Society for Pediatric Oncology and Hematology GPOH gGmbH | 57 | 2023-01-10 | 2024-05-16 |
| Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT Toripalimab, Induction chemotherapy and concurrent chemoradiation - Nasopharyngeal Cancer | Phase 2 | Recruiting | Fudan University | 198 | 2022-07-02 | 2022-11-29 |
| Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer Placebo (Aqua Pro-Injection), Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy), Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy) - Nasopharyngeal Cancer | Phase 1 / Phase 2 | Active not recruiting | PT. Prodia Stem Cell Indonesia | 15 | 2022-04-30 | 2026-02-25 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors TAK-500, Pembrolizumab, Tocilizumab - Pancreatic Cancer, Hepatocellular Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 61 | 2022-04-14 | 2026-01-22 |
| Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer cisplatin and gemcitabine, induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab. - Nasopharyngeal Cancer | Phase 2 | Recruiting | National University Hospital, Singapore | 50 | 2022-03-28 | 2025-09-23 |
Showing 20 of 67. Sign in to see all of them.
Nasopharyngeal Neoplasms (67) · Nasopharyngeal Carcinoma (12) · Epstein-Barr Virus Infections (9) · Stomach Neoplasms (6) · Esophageal Neoplasms (5) · Head and Neck Neoplasms (5) · Liver Neoplasms (5) · Ovarian Neoplasms (5) · Pancreatic Neoplasms (5) · Prostatic Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (4) · Mouth Neoplasms (4)
Nasopharyngeal Diseases (67) · Neoplasms by Site (67) · Otorhinolaryngologic Diseases (67) · Otorhinolaryngologic Neoplasms (67) · Pharyngeal Diseases (67) · Pharyngeal Neoplasms (67) · Stomatognathic Diseases (67) · Neoplasms (64) · Head and Neck Neoplasms (62) · Neoplasms by Histologic Type (26) · Neoplasms, Glandular and Epithelial (23) · Carcinoma (19) · Digestive System Diseases (14) · Digestive System Neoplasms (13) · Gastrointestinal Diseases (13)
Cisplatin (13) · Gemcitabine (9) · Radiotherapy, Intensity-Modulated (6) · Fluorouracil (3) · Radiotherapy (3) · Capecitabine (2) · Carboplatin (2) · Chemoradiotherapy (2) · Dexamethasone (2) · Nivolumab (2) · camrelizumab (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Acupuncture Therapy (1) · Bevacizumab (1)
Sun Yat-sen University (13) · National University Hospital, Singapore (4) · Chinese University of Hong Kong (2) · Fudan University (2) · Hoffmann-La Roche (2) · National Cancer Centre, Singapore (2) · National Taiwan University Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University Health Network, Toronto (2) · Assuntina Sacco, M.D. (1) · Baylor College of Medicine (1) · Biotech Pharmaceutical Co., Ltd. (1) · Cancer Research UK (1) · Christian von Buchwald (1) · Cullinan Therapeutics Inc. (1)
China (23) · United States (15) · Singapore (7) · Hong Kong (4) · Canada (3) · Taiwan (3) · France (2) · Indonesia (2) · Australia (1) · Belgium (1) · Denmark (1) · Germany (1) · Italy (1) · Japan (1) · Malaysia (1)
Jun Ma, M.D. (4) · Anthony TC Chan, MD, FRCP (2) · Lillian Siu, MD (2) · A. Dimitrios Colevas (1) · A. Dimitrios Colevas, MD (1) · Assuntina Sacco, MD (1) · Boon Cher Goh (1) · Bryan Burmeister (1) · Chao-su Hu, M.D. (1) · Chaosu Hu, M.D. (1) · Christian Von Buchwald, MD, DMSc (1) · Chuangzhen Chen (1) · Jenq-Yuh Ko, M.D., Ph.D. (1) · Jianchuan Xia (1)
PMID 18971421, PMID 21358293, PMID 23255783, PMID 27567280, PMID 28837405, PMID 29584545, PMID 31150573, PMID 31373615, PMID 34989842, PMID 35098345, PMID 35986837, PMID 36787089, PMID 37851143, PMID 38135184, PMID 39353160, PMID 39800271, PMID 40443562, PMID 41469668, PMID 41667193
2017 (1), P01CA015396 (1), R01CA235633 (1), U19CA121503 (1)